Susanna Naggie, MD

Associate Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, 6th Floor - 6410, Durham, NC 27701
Phone (919) 684-2584
Email address susanna.naggie@duke.edu

Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine.  She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is an Associate Professor of Medicine with Tenure and currently holds joint appointments at the Duke Clinical Research Institute (DCRI, Director of ID Research), and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and the extrahepatic health outcomes attributed to HCV in persons with HIV infection. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease. She is the prior co-Chair of the AASLD/IDSA HCV Guidance Committee and is currently Chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee. For the past two years Dr. Naggie has served as the Medical Director of the Duke Department of Medicine Clinical Research Unit.

Education and Training

  • Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
  • Medical Resident, Medicine, Duke University, 2002 - 2005
  • M.D., Johns Hopkins University, 2002
Weight
-20

Publications

Morrison, Margaret, Heather Y. Hughes, Susanna Naggie, and Wing-Kin Syn. “Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?.” Dig Dis Sci 64, no. 12 (December 2019): 3394–3401. https://doi.org/10.1007/s10620-019-05861-7.

PMID
31643035
Full Text

Ocal, Selin, Andrew J. Muir, and Susanna Naggie. “Hepatitis C Behind and Beyond Bars: Targeting the US Prison Population and Changing North Carolina Prisoner Health Policy..” N C Med J 80, no. 6 (November 2019): 352–55. https://doi.org/10.18043/ncm.80.6.352.

PMID
31685570
Full Text

Alenezi, Fawaz, Gerald S. Bloomfield, Nwora Lance Okeke, Poonam Velagapudi, Loai Abudaqa, Nkechinyere Ijioma, Allison Dunning, et al. “Global Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus..” Am J Cardiol 124, no. 6 (September 15, 2019): 966–71. https://doi.org/10.1016/j.amjcard.2019.06.013.

PMID
31371060
Full Text

Lee, Tzu-Hao, Austin Chan, William E. Bryan, Lawrence Park, Mohamed Hashem, Mary Townsend, Cynthia A. Moylan, Rachel B. Britt, Steve S. Choi, and Susanna Naggie. “USAGE OF PPI REDUCES THE SVR RATE FOR HIV-HCV COINFECTED PATIENTS USING LEDIPASVIR/SOFOSBUVIR: A REAL-WORLD STUDY FROM MULTICENTER VA COHORT.” In Gastroenterology, 156:S1345–S1345. W B SAUNDERS CO-ELSEVIER INC, 2019.

Scholars@Duke

Gutierrez, Julio, Eli Zuckerman, Andrew Ustianowski, Susanna Naggie, Florin Caruntu, Natarajan Ravendhran, Samuel Sigal, et al. “EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR TREATMENT FOR 8 WEEKS IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS: ANALYSIS OF DATA POOLED FROM PHASE 2 AND 3 STUDIES.” In Gastroenterology, 156:S1218–S1218. W B SAUNDERS CO-ELSEVIER INC, 2019.

Scholars@Duke

Naggie, Susanna, Meredith Clement, Sam Lusk, Anu Osinusi, Tiffany Himmel, Joseph E. Lucas, Will J. Thompson, et al. “Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations..” Proteomics Clin Appl 13, no. 3 (May 2019). https://doi.org/10.1002/prca.201800006.

PMID
30058111
Full Text

Zuckerman, Eli, Julio Gutierrez, Andrew Ustianowski, Susanna Naggie, Florin Alexandru Caruntu, Natarajan Ravendhran, Samuel Sigal, et al. “Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies.” In Journal of Hepatology, 70:E251–E251. ELSEVIER, 2019.

Scholars@Duke

Naggie, Susanna, and Christian B. Ramers. “Sustained Virologic Response in People Who Inject Drugs and/or Who Are on Opioid Agonist Therapy: Is 90% Enough?.” Hepatol Commun 3, no. 4 (April 2019): 453–55. https://doi.org/10.1002/hep4.1347.

PMID
30976736
Full Text

Naggie, Susanna, Daniel S. Fierer, Michael D. Hughes, Arthur Y. Kim, Annie Luetkemeyer, Vincent Vu, Jhoanna Roa, et al. “Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals..” Clin Infect Dis, March 28, 2019. https://doi.org/10.1093/cid/ciy913.

PMID
31220220
Full Text

Pages